SCHEMBL29853539

SCHEMBL29853539

CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CC1CCCCC1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ C5AR1 P21730 2/20 0.62
▸ IL23R Q5VWK5 2/20 0.54
▸ MC4R P32245 2/20 0.54
▸ MC5R P33032 2/20 0.54
▸ MC3R P41968 2/20 0.54
▸ MC1R Q01726 2/20 0.54
▸ KISS1R Q969F8 4/20 0.54
▸ CXCR4 P61073 1/20 0.53
▸ CXCL8 P10145 5/20 0.52
▸ OPRM1 P35372 3/20 0.52
▸ OPRK1 P41145 3/20 0.52
▸ DPP3 Q9NY33 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31411096 0.97 C5AR1 (0.60) C5AR1IL23RMC4RMC5RMC3R
SCHEMBL29853326 0.95 C5AR1 (0.63) C5AR1IL23RMC4RMC5RMC3R
SCHEMBL31411094 0.93 C5AR1 (0.63) C5AR1IL23RMC4RMC5RMC3R
SCHEMBL13144634 0.93 C5AR1 (0.60) C5AR1IL23RMC4RMC5RMC3R
SCHEMBL29853485 0.92 C5AR1 (0.62) C5AR1IL23RMC4RMC5RMC3R
SCHEMBL29547115 0.91 C5AR1 (0.60) C5AR1KISS1RCXCR4DPP3
SCHEMBL30518034 0.90 IL23R (0.64) C5AR1IL23RMC4RMC5RMC3R
SCHEMBL13144891 0.88 KISS1R (0.58) C5AR1IL23RMC4RMC5RMC3R
SCHEMBL30711762 0.88 C5AR1 (0.55) C5AR1IL23RKISS1RCXCR4DPP3
SCHEMBL17642339 0.88 CTSL (0.57) IL23RKISS1RCXCR4CXCL8DPP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4308114-B1 C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES DOMPE FARM SPA (IT) 2026-02-11 — — EP claimed
EP-4397306-A1 C5AR1 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID Dompe' Farmaceutici S.P.A. (IT) 2024-07-10 — — EP claimed
US-20240180888-A1 C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES DOMPE' FARMACEUTICI SPA (IT) 2024-06-06 — — US claimed
EP-4059497-A1 C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES Dompé farmaceutici S.p.a. (IT) 2022-09-21 — — EP claimed
EP-4308114-B1 C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES DOMPE FARM SPA (IT) 2026-02-11 — — EP disclosed
EP-4397306-A1 C5AR1 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID Dompe' Farmaceutici S.P.A. (IT) 2024-07-10 — — EP disclosed
US-20240180888-A1 C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES DOMPE' FARMACEUTICI SPA (IT) 2024-06-06 — — US disclosed
US-11857600-B2 GPCR heteromer inhibitors and uses thereof GPCR THERAPEUTICS, INC. (KR) 2024-01-02 — — US disclosed
EP-4059497-A1 C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES Dompé farmaceutici S.p.a. (IT) 2022-09-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240180888-A1 C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES C5AR1, C5AR2, C3AR1 C5AR1 1/4885IL23R 97/4885MC4R 2706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback